RHYTHM PHARMACEUTICALS, INC. - COM (RYTM)

Historical Holders from Q4 2017 to Q3 2025

Symbol
RYTM on Nasdaq
CUSIP
76243J105
Type / Class
Equity / COM
Shares outstanding
63.6M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
66.5M
Holdings value
$4.2B
% of all portfolios
0.01%
Grand Portfolio weight change
+0%
Number of holders
225
Number of buys
125
Number of sells
-105
Average Value change %
+0%
Average buys %
+0.002%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 8.9% $263M 5.6M Baker Bros. Advisors LP Mar 31, 2025
RA CAPITAL MANAGEMENT, L.P. 8.7% $543M 5.56M RA Capital Management, L.P. Jun 30, 2025
PRIMECAP MANAGEMENT CO/CA/ 7.67% -16.4% $476M -$88.8M 4.88M -15.7% PRIMECAP MANAGEMENT CO/CA/ Jun 30, 2025
PERCEPTIVE ADVISORS LLC 6.8% $208M 4.42M Perceptive Advisors LLC Mar 31, 2025
BlackRock, Inc. 6.9% $205M 4.36M BlackRock, Inc. Mar 31, 2025
GOLDMAN SACHS GROUP INC 3% $85.4M 1.82M THE GOLDMAN SACHS GROUP, INC. Dec 31, 2024

Institutional Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 243 $24.5K +$3.23K $100.99 1
2025 Q2 66.5M $4.2B +$137M $63.19 225
2025 Q1 64.6M $3.42B -$18.8M $52.97 226
2024 Q4 64.9M $3.63B -$155M $55.98 202
2024 Q3 67.6M $3.54B -$89M $52.39 178
2024 Q2 69.3M $2.85B +$55.5M $41.06 165
2024 Q1 68M $2.94B +$57.2M $43.33 169
2023 Q4 80.3K $3.69M -$183K $45.97 3
2023 Q3 68.1M $1.56B +$52.4M $22.93 143
2023 Q2 66.2M $1.09B +$94.9M $16.49 116
2023 Q1 56.6M $1.01B -$50.4M $17.84 124
2022 Q4 62.3M $1.81B +$85.3M $29.12 115
2022 Q3 59.5M $1.45B +$425M $24.50 96
2022 Q2 44.3M $184M -$10.5M $4.15 77
2022 Q1 48.4M $557M +$5.26M $11.52 101
2021 Q4 48.4M $483M -$577K $9.98 89
2021 Q3 47.7M $623M +$5.07M $13.06 92
2021 Q2 47.3M $903M -$4.69M $19.58 100
2021 Q1 47.6M $1.01B +$148M $21.27 121
2020 Q4 40.5M $1.2B +$38.7M $29.73 113
2020 Q3 39.2M $851M -$43.7M $21.67 114
2020 Q2 41.2M $919M +$11.8M $22.30 87
2020 Q1 40.8M $621M -$33.7M $15.22 79
2019 Q4 40M $918M +$205M $22.96 88
2019 Q3 31.2M $674M +$64.8M $21.59 83
2019 Q2 28.2M $620M +$8.6M $22.00 81
2019 Q1 30.9M $846M -$21.9M $27.41 84
2018 Q4 31.7M $851M +$12.8M $26.88 72
2018 Q3 30.3M $885M -$10.3M $29.17 74
2018 Q2 31M $966M +$213M $31.26 84
2018 Q1 20.4M $406M -$5.86M $19.90 52
2017 Q4 21.6M $628M +$507M $29.06 64